Pneumococcal conjugate vaccines: A review

Minerva Medica

Volumn 98, Issue 2, 2007, Pages 131-143

  Galiza, E P ^a   Heath, P T ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Pneumococcal infections; Streptococcus pneumoniae; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PENICILLIN G; PLACEBO; PNEUMOCOCCUS VACCINE;

BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG CONJUGATION; HUMAN; IMMUNE RESPONSE; INJECTION SITE SWELLING; NONHUMAN; PROGNOSIS; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

CARRIER STATE; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; VIRULENCE FACTORS;

EID: 34447538309     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Center KJ. Prevenar™ vaccination: Review of the global data, 2006. Vaccine 2007;25:3085-9.
2. D'Ancona F, Alfonsi V, Caporali M, Ranghiasci A, Ciofi Degli Atti M. Pneumococcal conjugate, meningococcal C and varicella vaccination in Italy. Euro Surveill 2007;12.
3. Austrian R. Some aspects of pneumococcal carrier state. J Antimicrob Chemother 1986;18:35-45.
4. Obaro SK. The new pneumococcal vaccine. Clin Microbiol Infect 2002;8:623-33.
5. Gray BM, Converse 3d GM, Dillon Jr HC. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980;142:923-33.
6. O'Brien KL, Santosham M. Potential impact of conjugate pneumococcal vaccines in pediatric pneumoccocal diseases. Am J Epidemiol 2004;159:634-44.
7. Bruyn GA, Zegers BJ, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992;14:251-62.
8. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001;65:187-207.
9. Paton JC, Andrew PW, Boulnois GJ. Mitchell TJ. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu Rev Microbiol 1993;47:89-115.
10. Obaro SK, Adegbola RA. The pneumococcus: vaccines, carriage, disease and conjugate vaccines. J Med Microbiol 2002;2:98-104.
11. Hendley JO, Sande MA, Stewart PM, Gwaltney JM Jr. Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis 1975;132:55-61.
12. Pebody RG, Hellenbrand W, D'Ancona F, Ruutu P. Pneumococcal disease surveillance in Europe. Euro Surveill 2006;11:171-8.
13. Klei JO. The epidemiology of pnumococcal disease in infants and children. Rev Infect Dis 1981;3:246-53.
14. Barraf LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993;12:389-94.
15. Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan D, Musher DM et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the drug resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
16. Austrian R. The pneumococcus at the millennium: not down, not out. J Infect Dis 1999;179 Suppl 2:S338-41.
17. Wright AE, Parry Morgan W, Colebrook L, Dodgson RW. Prophylactic inoculation against pneumococcal infections, and on the results which have been achieved by it. Lancet 1914;1:1-101.
18. Felton L, Baily G. Biologic significance of the soluble specific substance of pneumococci. J Infect Dis 1926;38:131-44.
19. Smillie W, Warnock G, White H. A study of a type 1 pneumococcus epidemic at the state hospital in Worcester, MA. Am J Public Health 1938;28:293-302.
20. MacLeod C, Hodges R, Heidleberger M, Bernhard W. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-62.
21. Austrian R, Gold J. Pneumococcal bacteraemia with special reference to bacteraemic pneumococcal pneumonia. Ann Intern Med 1964;60:759-76.
22. Koskela M, Leinonen M, Haiva VM, Timonen M, Makela PH. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986;5:45-50.
23. Jackson LA, Neuzil KM, Yu O, Barlow WE, Adams AL, Hanson CA et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747-55.
24. Wadwa RP, Feigin RD. Pneumococcal vaccine: an update. Pediatrics 1999;103(5 Pt 1):1035-7.
25. Butler JC, Brieman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine: an evaluation of current recommendations. JAMA 1993;270:1826-31.
26. Poland GA. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine 1999;17:1674-9.
27. Health Protection Agency. Invasive pneumococcal infection, England and Wales: 2000. CDR Wkly 2003:3-9.
28. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003;3:71-8.
29. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA et al. Efficacy of pneumococcal vaccine in adults: a meta-analysis of randomised controlled trials. Arch Int Med 1994;154:2666-77.
30. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part 1. Efficacy of PPV in the elderly: a comparison of meta-analysis. Eur J Epidemiol 2004;19:353-63.
31. Breukels MA, Rijkers GT, Voorhost-Ogink MM, Zegers BJ, Sanders LA. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. J Infect Dis 1999;179:1152-6.
32. Stein KR. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165 Suppl 1:S49-52.
33. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
34. Avery OT, Goebel WF. Chemoimmunological studies on conjugated carbohydrate proteins: II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929;50:533-50.
35. Peeters CC, Tenbergen-Meekes AM, Haagmans B, Evenberg D, Poolman JT, Zegers BJ et al. Pneumococcal conjugate vaccines. Immuno Lett 1991;30:267-74.
36. Obaro SK, Huo Z, Banya WA, Henderson DC, Monteil MA, Leach A et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997;16:1135-40.
37. Ahman H, Kayhty H, Tamminen P, Vuorella A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15:134-9.
38. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;116:1060-4.
39. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-63.
40. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for the development of a conjugate vaccine. J Infect Dis 1995;171:885-9.
41. st interscience conference on antimicrobial agents and chemotherapy. Vaccine 2003;21: 1562-71.
42. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente vaccine study center group. Pediatr Infect Dis J 2000;19:187-95.
43. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-5.
44. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E et al. Efficacy of a pneumococcal conjugate vaccine against otitis media. N Engl J Med 2001;344:403-9.
45. Lakshman R, Murdoch C, Race G, Burkinshaw R, Shaw L, Finn A. Pnemococcoal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infant. Arch Dis Child 2003;88:211-4.
46. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002;185:927-36.
47. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM et al. Changing epidemiology of invasive pneumococcal disease mong older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-51.
48. Poehling KA, Talbot TR. Griffin MR. Craig AS, Whitney CG, Zell E et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1468-74.
49. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-1998-2003. United States. Morbid Mortal Weekly Rep 2005;54:893-7
50. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-502.
51. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 2000;356:1210-1.
52. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O et al. Reduction of nasopharyngeal carriage of pneumococcal disease during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
53. Obaro SK, Adegbola RA, Banya WAS, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996;348:271-2.
54. Givon-Lavi N, Dagan R, Fraser D, Yagupsky P, Porat N. Marked differences in pneumococcal carriage and resistance patterns between day care centres located within a small area. Clin Infect Dis 1999;29:1274-80.
55. Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J et al. Effect of pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media. Lancet 2003;361:2189-95.
56. Hsu K, Pelton D, Heisey-Grove S, Hashemi J, Klein J. Conjugate vaccine era serotype-specific surveillance for invasive pneumococcal disease in Massachusetts children: program and abstracts of the 21st annual meeting of the European society for pediatric infectious diseases, 2003, April 9-11, Giardini Naxos, Italy.
57. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J et al. Postlicensure surveillance or pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004;23:485-9.
58. Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D. Progress in the prevention of pneumococcal infection. CMAJ 2005;173:1149-51.
59. Roche PW, Krause VL, Bartlett M, Coleman D, Cook H, Davis C, et al. Invasive pneumococcal disease in Australia. Commun Dis Intell 2006;30:80-92.
60. Tarallo L, Tancredi F, Schito G, Marchese A, Bella A. Active surveillance of Streptococcus pneumoniae bacteremia in Italian children. Vaccine 2006;24:6938-43.
61. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo controlled trial. Lancet 2005;365:1139-46.
62. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N et al. A trial of a nine-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8.
63. Overturf GD. Pneumococcal vaccination of children. Semin Pediatr Infect Dis 2002;13:155-61.
64. Vernacchio L, Neufeld EJ, MacDonald K, Kurth S, Murakami S, Hohne C et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998;133:275-8.
65. King JC Jr, Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997;99:575-80.
66. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A et al. Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
67. Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in Southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996;174:1352-5.
68. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63.